WO2008099917A1 - 抗hmgb-1抗体を含む臓器移植拒絶抑制剤 - Google Patents

抗hmgb-1抗体を含む臓器移植拒絶抑制剤 Download PDF

Info

Publication number
WO2008099917A1
WO2008099917A1 PCT/JP2008/052520 JP2008052520W WO2008099917A1 WO 2008099917 A1 WO2008099917 A1 WO 2008099917A1 JP 2008052520 W JP2008052520 W JP 2008052520W WO 2008099917 A1 WO2008099917 A1 WO 2008099917A1
Authority
WO
WIPO (PCT)
Prior art keywords
hmgb
antibody
agent
organ transplantation
rejection
Prior art date
Application number
PCT/JP2008/052520
Other languages
English (en)
French (fr)
Inventor
Yohichi Yasunami
Ikuro Maruyama
Shingo Yamada
Original Assignee
Fukuoka University
Kagoshima University
Shino-Test Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fukuoka University, Kagoshima University, Shino-Test Corporation filed Critical Fukuoka University
Priority to EP08711350A priority Critical patent/EP2123298A4/en
Priority to JP2008558147A priority patent/JP5285437B2/ja
Priority to US12/527,159 priority patent/US20100173277A1/en
Publication of WO2008099917A1 publication Critical patent/WO2008099917A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

　本発明は、臓器移植の際に起こる拒絶反応、特に、糖尿病の治療において有用な膵島移植における拒絶反応を抑制するのに有効な手段を提供することを目的とする。本発明により、HMGB-1に対する抗体が、膵島移植の際の拒絶反応を抑制し、移植された膵島の生着を促進することが明らかにされた。そこで本発明は、抗HMGB-1抗体を含む臓器移植拒絶抑制剤を提供するものである。
PCT/JP2008/052520 2007-02-15 2008-02-15 抗hmgb-1抗体を含む臓器移植拒絶抑制剤 WO2008099917A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08711350A EP2123298A4 (en) 2007-02-15 2008-02-15 MEANS FOR SUPPRESSING THE SLIP IN ORGAN TRANSPLANTATIONS WITH ANTI-HMGB-1 ANTIBODIES
JP2008558147A JP5285437B2 (ja) 2007-02-15 2008-02-15 抗ｈｍｇｂ−１抗体を含む臓器移植拒絶抑制剤
US12/527,159 US20100173277A1 (en) 2007-02-15 2008-02-15 Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034280 2007-02-15
JP2007-034280 2007-02-15

Publications (1)

Publication Number Publication Date
WO2008099917A1 true WO2008099917A1 (ja) 2008-08-21

Family

ID=39690142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052520 WO2008099917A1 (ja) 2007-02-15 2008-02-15 抗hmgb-1抗体を含む臓器移植拒絶抑制剤

Country Status (5)

Country Link
US (1) US20100173277A1 (ja)
EP (1) EP2123298A4 (ja)
JP (1) JP5285437B2 (ja)
TW (1) TW200846366A (ja)
WO (1) WO2008099917A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012025673A (ja) * 2010-07-20 2012-02-09 Taisho Pharmaceutical Co Ltd Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法
WO2015152429A1 (ja) * 2014-04-03 2015-10-08 学校法人獨協学園獨協医科大学 移植免疫応答の抑制方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5241518B2 (ja) * 2007-02-15 2013-07-17 国立大学法人九州大学 抗ｈｍｇｂ−１抗体を含む間質性肺疾患治療剤
TW200902063A (en) * 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
FI20105715A0 (fi) 2010-06-18 2010-06-18 Helsingin Yliopisto Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine
US11191808B2 (en) * 2014-07-04 2021-12-07 Industry-University Cooperation Foundation Hanyang University Pharmaceutical composition for suppressing cell transplant rejection
CN109406794A (zh) * 2018-12-13 2019-03-01 福建医科大学 与预测肝移植术后排斥反应相关的蛋白标志物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003096099A (ja) * 2001-07-13 2003-04-03 Shino Test Corp ヒトｈｍｇ−１に特異的に結合する抗体並びにこの抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
WO2006124477A2 (en) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases
WO2006138429A2 (en) * 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0964250B1 (en) * 1996-07-17 2007-06-27 Kaneka Corporation Diagnostic drugs for autoimmune diseases
BR9810985A (pt) * 1997-07-08 2000-08-15 Dsm Nv Aplicação tópica de uma combinação de peróxido de benzoìla e um segundo ingrediente ativo
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
NZ521939A (en) * 2000-05-22 2004-04-30 Univ New York Inducing an immune response to amyloid beta peptides and amyloid deposits using a synthetic non-amylogenic but immunogenic peptide
CA2447576C (en) * 2001-05-15 2014-04-08 North Shore-Long Island Jewish Research Institute Use of hmg fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1812065A4 (en) * 2004-10-22 2009-09-02 Medimmune Inc HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
EP2380983A3 (en) * 2006-05-05 2012-12-05 TransTech Pharma Inc. RAGE fusion proteins, formulations, and methods of use thereof
JP5241518B2 (ja) * 2007-02-15 2013-07-17 国立大学法人九州大学 抗ｈｍｇｂ−１抗体を含む間質性肺疾患治療剤
TW200902063A (en) * 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003096099A (ja) * 2001-07-13 2003-04-03 Shino Test Corp ヒトｈｍｇ−１に特異的に結合する抗体並びにこの抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
WO2006124477A2 (en) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases
WO2006138429A2 (en) * 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
DUMITRIU I.E. ET AL.: "Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products", J. IMMUNOL., vol. 174, no. 12, 2005, pages 7506 - 7515, XP008112031 *
ERRATUM IN: TRANSPLANTATION, vol. 43, no. 4, April 1987 (1987-04-01), pages 608
GOLDSTEIN D.R.: "The identify of innate immune activators in organ transplantation: origins from within or exterior to the host?", AMERICAN JOURNAL OF TRANSPLANTATION, vol. 7, no. 7, July 2007 (2007-07-01), pages 1692 - 1694, XP008112032 *
HUANG Y. ET AL.: "Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection", AM. J. TRANSPLANT., vol. 7, no. 4, 28 February 2007 (2007-02-28), pages 799 - 808, XP008112033 *
MOSER B. ET AL.: "Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation", AMERICAN JOURNAL OF TRANSPLANTATION, vol. 7, no. 5, PART 1, February 2007 (2007-02-01), pages 293 - 302, XP008112083 *
NAKANO T. ET AL.: "Role of Antinuclear Antibodies in Experimental and Clinical Liver Transplantation", TRANSPLANTATION PROCEEDINGS, vol. 38, no. 10, 2006, pages 3605 - 3606, XP005804112 *
OHTSUKA K ET AL., TRANSPLANTATION, vol. 64, no. 4, 27 August 1997 (1997-08-27), pages 633 - 9
ROVERE-QUERINI P. ET AL.: "HMGB1 is an endogenous immune adjuvant released by necrotic cells", EMBO REP., vol. 5, no. 8, 2004, pages 825 - 830, XP008112030 *
See also references of EP2123298A4
SUTTON R ET AL.: "Isolation of rat pancreatic islets by ductal injection of collagenase", TRANSPLANTATION, vol. 42, no. 6, December 1986 (1986-12-01), pages 689 - 91, XP001069284
YAMAHARA K. ET AL.: "High-mobility group box 1 protein (HMGB1) released by cell transplantation plays an important role in the therapeutic effects for treating chronic ischemic heart failure", CIRCULATION, vol. 114, no. 18, 2006, pages 566 - 567, XP008112082 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012025673A (ja) * 2010-07-20 2012-02-09 Taisho Pharmaceutical Co Ltd Ｎｃｘを標的とした単離膵島ならびに移植膵島障害の新規制御法
WO2015152429A1 (ja) * 2014-04-03 2015-10-08 学校法人獨協学園獨協医科大学 移植免疫応答の抑制方法
JPWO2015152429A1 (ja) * 2014-04-03 2017-04-13 学校法人獨協学園獨協医科大学 移植免疫応答の抑制方法

Also Published As

Publication number Publication date
TW200846366A (en) 2008-12-01
JPWO2008099917A1 (ja) 2010-05-27
US20100173277A1 (en) 2010-07-08
EP2123298A4 (en) 2011-09-28
EP2123298A1 (en) 2009-11-25
JP5285437B2 (ja) 2013-09-11

Similar Documents

Publication Publication Date Title
WO2008099917A1 (ja) 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
WO2009112245A9 (en) Antibody against the csf-1 r
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2006127768A3 (en) Microscale micropatterned engineered in vitor tissue
WO2008143954A3 (en) Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2007140371A8 (en) Antibodies and immunoconjugates and uses therefor
WO2006121631A3 (en) Real time imaging during solid organ transplant
WO2010120757A3 (en) Regeneration of tissue without cell transplantation
TW200714283A (en) Method and composition for treating peripheral vascular diseases
WO2006119256A3 (en) Volumetric grafts for treatment of fistulae and related methods and systems
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2008034013A3 (en) Medical devices and methods of making the same
DK1858575T3 (da) Pakke til medikoindretning
WO2012020006A3 (en) Anti-fap antibodies and methods of use
WO2006083782A3 (en) Directed differentiation of embryonic stem cells and uses thereof
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
WO2009111300A3 (en) Gradient coating for biomedical applications
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
WO2007081620A3 (en) Stent with integral filter
WO2010045388A3 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2008157570A3 (en) Device and method for restoration of the condition of blood
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711350

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008558147

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008711350

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12527159

Country of ref document: US